Clinical Trials
1
Active:0
Completed:1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Adrenomedullin and Outcome in Severe Sepsis and Septic Shock
Completed
- Conditions
- Severe SepsisSeptic Shock
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Sphingotec GmbH
- Target Recruit Count
- 596
- Registration Number
- NCT02393781
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CH Jolimont, La Louvière, Belgium
🇧🇪Clinique St Pierre, Ottignies, Belgium
News
Real-World Evidence Validates Proenkephalin A 119-159 as Superior Kidney Function Biomarker in Critical Care
A comprehensive real-world study of over 4,000 ICU patients demonstrates that Proenkephalin A 119-159 (penKid) significantly outperforms traditional creatinine markers in detecting acute kidney injury and assessing kidney function.